On October 13, 2025, AbbVie announced it will present new data from its antibody-drug conjugate (ADC) platform at the upcoming ESMO 2025 Congress, highlighting progress in targeted therapies for difficult-to-treat solid tumors[4][5]. Additionally, the FDA approved an updated indication for Rinvoq, broadening its use for adults with inflammatory bowel disease, which is significant given Rinvoq's status as a key revenue driver[3]. Despite these positive developments, AbbVie’s stock price remained stable, closing at $230.31 on October 13, 2025, down 0.08% from the previous session, indicating that the news was largely anticipated or already reflected in the share price.